Avicanna Inc. (TSX:AVCN)

Market Cap	27.31M
Revenue (ttm)	25.34M
Net Income (ttm)	-2.53M
Shares Out	113.81M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,726
Average Volume	81,358
Open	0.2650
Previous Close	0.2650
Day's Range	0.2400 - 0.2700
52-Week Range	0.2100 - 0.5500
Beta	0.33
RSI	40.63
Earnings Date	Aug 14, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.